Ftse Mib
38.499,75
-0,24%
DAX
22.840,03
-0,70%
S&P 500
5.770,20
0,55%
NASDAQ
18.196,22
0,70%
Bitcoin
82.094,30
1,87%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NeuroSense Therapeutics Ltd (NRSN) NeuroSense Therapeutics Ltd (NRSN) Notizie

NeuroSense Therapeutics Ltd

NRSN
1,13
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:34:11
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/1/202515:00PRNUSNeuroSense Regains Compliance with Nasdaq's Minimum Equity..
23/12/202415:00PRNUSNeuroSense Therapeutics Enters Binding Term Sheet to Advance..
18/12/202416:25PRNUSNeuroSense Provides Business Update and Third Quarter 2024..
11/12/202415:25PRNUSNeuroSense Receives Positive FDA Feedback on Phase 3 Study..
04/12/202414:30PRNUSNeuroSense Announces Completion of PARADIGM Study..
02/12/202414:30PRNUSNeuroSense Therapeutics Announces $5 Million Private..
21/11/202415:20PRNUSNeuroSense Therapeutics to Participate in the 2024..
28/10/202413:30PRNUSNeuroSense Secures Key FDA Meeting to Advance its Phase 3..
24/10/202414:30PRNUSNew Analysis Shows PrimeC Significantly Improves Key miRNAs..
15/10/202415:15PRNUSNeuroSense Advances Plans for Early Commercialization of..
09/10/202415:00PRNUSNeuroSense Therapeutics Plans to File for Early..
07/10/202415:00PRNUSNeuroSense Therapeutics Announces Acceptance of Two PrimeC..
24/9/202415:05PRNUSNeuroSense Therapeutics Granted Key U.S. Patent for Novel..
24/9/202415:00PRNUSNeuroSense Regains Compliance with NASDAQ Minimum Bid Price..
30/8/202423:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/8/202422:30PRNUSNeuroSense Therapeutics Announces Receipt of Nasdaq Minimum..
28/8/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/8/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/8/202422:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/8/202422:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/8/202420:00PRNUSNeuroSense Therapeutics Announces Private Placement with..
07/8/202415:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/8/202415:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/8/202415:15PRNUSNeuroSense Therapeutics Announces Positive Biomarker Data..
09/7/202415:27PRNUSNeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to..
01/7/202414:00PRNUSNeuroSense Demonstrates Statistically Significant Efficacy..
24/6/202415:00PRNUSNeuroSense Management Provides Corporate Update and First..
21/6/202422:30PRNUSNeuroSense Receives Delisting Notice from Nasdaq and Intends..
20/5/202415:00PRNUSNeuroSense Vice President of R&D Shiran Zimri, Ph.D. to..
14/5/202415:05PRNUSNeuroSense Partners with PhaseV to Optimize Upcoming ALS..
07/5/202414:45PRNUSNeuroSense Announces New Positive Data Analysis from..
02/5/202415:19PRNUSNeuroSense Announces First Quarter 2024 Business Update
22/4/202414:30PRNUSNeuroSense and Genetika+ Initiate Precision Medicine..
18/4/202414:30PRNUSNeuroSense Presents Positive Data Validating Phase 2b..
12/4/202414:30PRNUSNeuroSense to Present PARADIGM Data at the American Academy..
11/4/202401:16PRNUSNeuroSense Announces Pricing of $4.5 Million Registered..
09/4/202414:30PRNUSNeuroSense Collaborates with Lonza to Identify Exosome-based..
05/4/202415:29PRNUSNeuroSense Announces Year End 2023 Financial Results and..
Apertura: Min: Max:
Chiusura: 1,13

La tua Cronologia

NASDAQ
NRSN
NeuroSense Therapeutics
EU
SCHP
Seche Environnement
HUOB
DHTETH
dHEDGE DAO
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci